Celgene

Celgene Corporation was a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. Celgene was acquired by Bristol Myers Squibb (BMS) in November 2019 and its operations are now consolidated under BMS. No public developer API has been identified; engagement is organized through BMS clinical trials, study connect, and investigator-sponsored research portals.

Celgene is profiled on the APIs.io network. Tagged areas include Biopharmaceutical, Clinical Trials, Oncology, Pharma, and Fortune 500.

🌐 Visit website 📡 Source on GitHub

3.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

BiopharmaceuticalClinical TrialsOncologyPharmaFortune 500

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.7/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.3 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/celgene: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Celgene Domain Security

DMARC

SECURITY

Press 5

Recent news and press coverage referencing this provider.

Get Started 1

Portal, sign-up, and the first successful call

Clinical Trials

Clinical Trials

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

LinkedIn

Website

Website

Other 3

Properties that don't map to a standard resource type

Parent Company

Parent Company

Study Connect

Study Connect

Research Pipeline

Research Pipeline

Source (apis.yml)

aid: celgene
url: https://raw.githubusercontent.com/api-evangelist/celgene/refs/heads/main/apis.yml
name: Celgene
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/celgene.png
tags:
- Biopharmaceutical
- Clinical Trials
- Oncology
- Pharma
- Fortune 500
created: '2024-01-15'
modified: '2026-04-23'
specificationVersion: '0.23'
description: Celgene Corporation was a global biopharmaceutical company focused on the discovery, development, and commercialization
  of innovative therapies for cancer and immune-inflammatory diseases. Celgene was acquired by Bristol Myers Squibb (BMS)
  in November 2019 and its operations are now consolidated under BMS. No public developer API has been identified; engagement
  is organized through BMS clinical trials, study connect, and investigator-sponsored research portals.
apis: []
common:
- type: DomainSecurity
  url: security/celgene-domain-security.yml
- type: GitHubOrganization
  url: https://github.com/celgene-research
- type: LinkedIn
  url: https://www.linkedin.com/company/celgene
- type: Website
  url: https://www.celgene.com
- type: Parent Company
  url: https://www.bms.com
- type: Clinical Trials
  url: https://www.bmsclinicaltrials.com/
- type: Study Connect
  url: https://www.bmsstudyconnect.com/
- type: Research Pipeline
  url: https://www.bms.com/researchers-and-partners/in-the-pipeline.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com

Celgene

Kin Score

Security Posture 1

Celgene Domain Security

Press 5

Celgene to use Exscientia's AI platform in effort ...

Exscientia announces multi-target, AI-driven drug ...

Exscientia announces new AI pharma collaboration

Celgene and Evotec's partner Exscientia enter 3-year AI ...

Exscientia Raises US$26 Million in Series B Financing ...

Resources